Meeting report--3rd Neuroblastoma Research Symposium, Liverpool, 6-7th November, 2013.
Meeting report--3rd Neuroblastoma Research Symposium, Liverpool, 6-7th November, 2013.
复制标题
会议报告——第三届神经母细胞瘤研究研讨会，利物浦，2013 年 11 月 6-7 日。
DOI：
10.1002/pbc.25087
复制
发表时间：
2014
影响因子：
3.2
通讯作者：
Bell E
中科院分区：
文献类型：
--
作者：
Bell E
神经母细胞瘤是发育中的神经嵴的胚胎恶性肿瘤。尽管治疗方法有所改善，但高风险疾病患者的预后仍然很糟糕。对这种神秘癌症的兴趣导致了快速变化的研究前景，我们报告了在第三届神经母细胞瘤研究研讨会上讨论的四个主题的最新进展：(1)神经母细胞瘤的表观遗传特征和肿瘤发展的表观遗传控制，(2)靶向MYCN的新方法，(3)有价值的内模和(4)基于正常交感神经元发育的知识改进分化治疗。通过热烈的讨论，我们对具有协同作用的联合疗法的发展有了很好的机制理解，这提供了最大的希望。药物协同作用增强了疗效，但也增强了特异性，后者对于减少幼儿的长期副作用至关重要。儿科血癌杂志2014；61:1711-1713。©2014 Wiley期刊公司
Neuroblastoma is an embryonal malignancy of the developing neural crest. Despite improvements in treatment, prognoses remain dire for patients with high‐risk disease. Interest in this enigmatic cancer has led to a rapidly changing research landscape and we report on the recent advances in four themes that were discussed at the 3rd Neuroblastoma Research Symposium: (1) The epigenetic signature of neuroblastoma and the epigenetic control of tumour development, (2) novel approaches to targeting MYCN, (3) valuablein vivomodelling and (4) improving differentiation therapies based on a knowledge of normal sympathetic neuron development. Through lively discussion, the development of combined therapies with synergistic effects for which we have a good mechanistic understanding emerged as offering greatest promise. Drug synergies enhance efficacy but also specificity, the latter crucial for reducing long‐term side effects in young children. Pediatr Blood Cancer 2014;61:1711–1713. © 2014 Wiley Periodicals, Inc.